Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.95 EUR
Change Today +0.075 / 4.00%
Volume 700.0K
COX On Other Exchanges
EN Paris
As of 11:35 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

nicox sa (COX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/25/14 - €2.78
52 Week Low
08/6/14 - €1.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NICOX SA (COX)

Related News

No related news articles were found.

nicox sa (COX) Related Businessweek News

View More BusinessWeek News

nicox sa (COX) Details

NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.

124 Employees
Last Reported Date: 04/13/15
Founded in 1996

nicox sa (COX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €417.7K
Compensation as of Fiscal Year 2013.

nicox sa (COX) Key Developments

Nicox Sa Reports Sales Results for the First Quarter Ended March 31, 2015; Provides Sales Guidance for the Year 2015

Nicox SA reported sales results for the first quarter ended March 31, 2015. The company reported revenues in the first three months of 2015 totaled €2.1 million and consisted exclusively of European and International product sales These compare to €0.9 million in the first quarter of 2014, showing a strong progress over the same period of the previous year. The company expects a continuous progression and growth of the revenues throughout the rest of 2015.

Nicox S.A. Announces New Appointment to the Board of Directors

Nicox S.A. announced appointment to the Board of Directors. Three new appointments to the Board of Directors: Adrienne Graves, former CEO of Santen Inc. to replace Vicente Anido; Luzi von Bidder, former Chairman of Acino Holding AG and former Chairman and CEO of Novartis Ophthalmics AG, to replace Vaughn Kailian; and Les Kaplan, former Executive Chairman of Aciex Therapeutics Inc. The company announced the appointment of Michael Bergamini, Ph.D. as Chief Scientific Officer and Executive Vice President of Nicox, with more than 30 years in ophthalmology including in the discovery, translation, development, registration and launch of more than a dozen ophthalmic drug and device products. And also appointment of Sandrine Gestin as Finance Director of Nicox, joining the company's Executive Committee. Sandrine has over 25 years of experience in accounting and finance and joined Nicox in 1999.

Nicox SA Announces Consolidated Earnings Results for the Year Ended December 31, 2014

Nicox SA announced consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenues of EUR 5.982 million compared to EUR 0.436 million a year ago. This significant increase reflects the launch of new products, acquisitions and investment in the group's commercial operations. Operating loss was EUR 21.779 million compared to EUR 11.003 million a year ago. Loss before income was EUR 21.550 million compared to EUR 11.416 million a year ago. Net loss was EUR 22.892 million compared to EUR 18.145 million a year ago. Total comprehensive loss attributable to equity holders of the parent was EUR 15.995 million compared to EUR 17.793 million a year ago. Basic and diluted loss per attributable to equity holders of the parent was EUR 0.28 compared to EUR 0.25 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COX:FP €1.95 EUR +0.075

COX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COX.
View Industry Companies

Industry Analysis


Industry Average

Valuation COX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICOX SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at